Clinical trial · Interventional
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer Patients With PARP Inhibitors Resistance: a Phase II Clinical Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
At present, the treatment of recurrent ovarian cancer after PARP inhibitor therapy is quite challenging, and there is no research on the application of hyperthermic intraperitoneal chemotherapy(HIPEC) for the above-mentioned patients. Therefore, this study aims to explore the safety and efficacy of secondary cytoreduction combined with hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer after maintenance therapy with PARP inhibitors through a single-center, prospective, single-arm, phase II clinical trial. The goal is to explore the treatment options for ovarian cancer patients in the era of PARP inhibitors, thereby improving the overall treatment level and prognosis of ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperthermic intraperitoneal chemotherapy | Drug | Hyperthermic Intraperitoneal Chemotherapy | ALIAS |
| Secondary cytoreduction | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Recurrent Ovarian Cancer After PARPi Therapy
- description
- After treated with PARP inhibitors, patients have recurrent ovarian cancer and need a surgery.
- interventionNames
- Procedure: Secondary cytoreduction
- Drug: Hyperthermic intraperitoneal chemotherapy
Primary outcomes (1)
- measure
- PFS
- timeFrame
- Two years
- description
- Progression free survival
Secondary outcomes (1)
- measure
- OS
- timeFrame
- Two years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with previously diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; 2. Maintain treatment with PARP inhibitors before recurrence; 3. The imaging assessment is suitable, and the patient agrees to undergo further cytoreductive surgery; 4. The outcome of recurrent surgery is R0 or R1 resection; 5. Sign the informed consent form; 6. Age≥18 years old; Exclusion Criteria: 1. Patients with ovarian cancer excluded by pathological or clinical diagnosis; 2. Inappropriate imaging evaluation or physical intolerance for surgical patients; 3. Isolated lymph node recurrence 4. Patients who undergo unsatisfactory tumor reduction surgery (R2 resection) due to recurrence; 5. Patients who are unwilling to participate in the clinical trial.
References
Publications (0)
Data not yet available